Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | September 2009 |
| End Date: | April 2032 |
Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer
This is a research study to determine if hypofractionated image guided radiation therapy
(hypoIGRT) with proton therapy is a good way to treat early stage lung tumors for patients
who will not have surgery. HypoIGRT delivers higher daily doses of radiation over a shorter
period of time compared with conventional radiation. This is thought to deliver a more lethal
dose of radiation to the tumor and is more convenient with treatment being completed within
2-3 weeks compared to the typical 7-8 week course of conventional radiotherapy.
(hypoIGRT) with proton therapy is a good way to treat early stage lung tumors for patients
who will not have surgery. HypoIGRT delivers higher daily doses of radiation over a shorter
period of time compared with conventional radiation. This is thought to deliver a more lethal
dose of radiation to the tumor and is more convenient with treatment being completed within
2-3 weeks compared to the typical 7-8 week course of conventional radiotherapy.
Inclusion Criteria:
- Pathologically confirmed, by biopsy or cytology, non-small cell lung carcinoma
diagnosed within 3 months prior to study enrollment.
- T1, N0, M0 or T2, N0, M0. (AJCC Lung 7th Edition)
- At least 18 years old at the time of consent.
- Adequate bone marrow function.
- Medically inoperable. Medically operable candidates are allowed if they refuse
surgical resection.
- If the patient has a large pleural effusion, it must be biopsy negative.
Exclusion Criteria:
- Evidence of distant metastasis (M1) and/or nodal involvement (N1, N2, N3).
- Synchronous primary.
- T2 tumors > 5 cm; T3, T4 primary tumor.
- Previous radiotherapy for lung cancer.
- Concomitant local, regional, and/or systemic therapy during radiotherapy.
- Active systemic, pulmonary, and/or pericardial infection.
We found this trial at
1
site
2015 Jefferson St
Jacksonville, Florida 32206
Jacksonville, Florida 32206
(904) 588-1800
Principal Investigator: Bradford S Hoppe, MD, MPH
Phone: 877-686-6009
University of Florida Proton Therapy Institute When the University of Florida Proton Therapy Institute opened...
Click here to add this to my saved trials
